Total Payments
$36,814
2024 Payments
$12,637
Companies
9
Transactions
38
Medicare Patients
3,240
Medicare Billing
$709,838
Payment Breakdown by Category
Consulting$16,484 (44.8%)
Research$16,250 (44.1%)
Food & Beverage$2,066 (5.6%)
Other$1,531 (4.2%)
Travel$483.47 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,484 | 7 | 44.8% |
| Unspecified | $16,250 | 7 | 44.1% |
| Food and Beverage | $2,066 | 21 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,181 | 1 | 3.2% |
| Travel and Lodging | $483.47 | 1 | 1.3% |
| Honoraria | $350.00 | 1 | 1.0% |
Payments by Type
General
$20,564
31 transactions
Research
$16,250
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $30,466 | 16 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $4,359 | 6 | $0 (2024) |
| Galderma Laboratories, L.P. | $673.53 | 6 | $0 (2023) |
| Biofrontera Inc. | $575.60 | 3 | $0 (2019) |
| Allergan, Inc. | $275.18 | 3 | $0 (2021) |
| LEO Pharma AS | $230.00 | 1 | $0 (2020) |
| Genentech USA, Inc. | $103.85 | 1 | $0 (2018) |
| GENZYME CORPORATION | $82.97 | 1 | $0 (2019) |
| Sientra, Inc. | $48.75 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,637 | 9 | Regeneron Pharmaceuticals, Inc. ($11,456) |
| 2023 | $222.20 | 2 | Regeneron Healthcare Solutions, Inc. ($113.16) |
| 2022 | $9,769 | 5 | Regeneron Pharmaceuticals, Inc. ($9,750) |
| 2021 | $12,100 | 6 | Regeneron Pharmaceuticals, Inc. ($9,260) |
| 2020 | $360.26 | 2 | LEO Pharma AS ($230.00) |
| 2019 | $1,163 | 8 | Biofrontera Inc. ($466.40) |
| 2018 | $242.98 | 2 | Galderma Laboratories, L.P. ($139.13) |
| 2017 | $319.73 | 4 | Galderma Laboratories, L.P. ($161.78) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,172.50 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $705.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $352.50 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,181.40 | General |
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $6,444.00 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $483.47 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $141.45 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $135.85 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2023 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $109.04 | General |
| 01/26/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $113.16 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $750.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 06/06/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 05/23/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 05/12/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 12/17/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 12/13/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $250.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 08/27/2021 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: FACIAL AESTHETICS | ||||||
| 02/11/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | Cash or cash equivalent | $250.00 | Research |
| Study: A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) • Category: ONCOLOGY | ||||||
| 01/29/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2020 | LEO Pharma AS | — | Consulting Fee | Cash or cash equivalent | $230.00 | General |
| 02/22/2020 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $130.26 | General |
| 11/07/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $82.97 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF NEOADJUVANT CEMIPLIMAB FOR STAGE II TO IV (M0) CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) | Regeneron Pharmaceuticals, Inc. | $16,250 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 733 | 873 | $1.2M | $151,298 |
| 2022 | 17 | 697 | 788 | $1.1M | $142,993 |
| 2021 | 17 | 900 | 1,147 | $1.4M | $197,746 |
| 2020 | 20 | 910 | 1,175 | $1.6M | $217,801 |
Total Patients
3,240
Total Services
3,983
Medicare Billing
$709,838
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 233 | 284 | $562,226 | $68,552 | 12.2% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 105 | 159 | $190,782 | $24,579 | 12.9% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 92 | 101 | $141,911 | $12,628 | 8.9% |
| 15260 | Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | Office | 2023 | 14 | 15 | $42,985 | $10,344 | 24.1% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2023 | 14 | 14 | $31,312 | $7,174 | 22.9% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2023 | 28 | 32 | $60,978 | $6,931 | 11.4% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 52 | 53 | $47,958 | $5,527 | 11.5% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 35 | 38 | $48,294 | $4,560 | 9.4% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 20 | 20 | $16,364 | $2,147 | 13.1% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 26 | 30 | $21,856 | $2,141 | 9.8% |
| 13152 | Complicated repair of wound of eyelids, nose, ears, or lip, 2.6-7.5 cm | Office | 2023 | 13 | 13 | $19,071 | $1,787 | 9.4% |
| 12051 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | Office | 2023 | 12 | 13 | $10,896 | $1,475 | 13.5% |
| 13151 | Complicated repair of wound of eyelids, nose, ears, or lip, 1.1-2.5 cm | Office | 2023 | 11 | 11 | $13,798 | $1,256 | 9.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 33 | 43 | $3,676 | $1,220 | 33.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 34 | 35 | $10,864 | $630.00 | 5.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,389 | $346.92 | 25.0% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 237 | 279 | $518,866 | $66,795 | 12.9% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2022 | 89 | 120 | $135,936 | $17,822 | 13.1% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2022 | 78 | 84 | $112,030 | $10,538 | 9.4% |
| 15260 | Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | Office | 2022 | 13 | 13 | $35,465 | $8,704 | 24.5% |
| 14060 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | Office | 2022 | 16 | 16 | $33,794 | $8,469 | 25.1% |
| 14061 | Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.1-30.0 sq cm | Office | 2022 | 13 | 13 | $35,155 | $8,247 | 23.5% |
| 17313 | Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | Office | 2022 | 27 | 31 | $53,816 | $6,781 | 12.6% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2022 | 33 | 34 | $40,674 | $4,054 | 10.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 32 | 32 | $27,296 | $3,204 | 11.7% |
About Dr. Anna Bar, MD
Dr. Anna Bar, MD is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326053836.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Bar, MD has received a total of $36,814 in payments from pharmaceutical and medical device companies, with $12,637 received in 2024. These payments were reported across 38 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($16,484).
As a Medicare-enrolled provider, Bar has provided services to 3,240 Medicare beneficiaries, totaling 3,983 services with total Medicare billing of $709,838. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties MOHS-Micrographic Surgery
- Location Portland, OR
- Active Since 07/31/2006
- Last Updated 03/29/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1326053836
Products in Payments
- LIBTAYO (Biological) $33,643
- Ameluz (Drug) $459.20
- AMELUZ (Drug) $116.40
- BOTOX COSMETIC (Biological) $109.68
- Erivedge (Biological) $103.85
- LIBTAYO (Drug) $82.97
- SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAT IMPLANT (Device) $48.75
- BOTOX (Biological) $19.84
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Andrew Blauvelt, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Eric Simpson, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Benjamin Ehst, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $1.5M
Dermatology $1.5M
Dr. Jason Hawkes, Md, Ms, MD, MS
Dermatology — Payments: $876,779
Dermatology $876,779
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824